1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...
The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...
Forbes contributors publish independent expert analyses and insights. I write about finance, innovation, climate and sustainability Europe’s next wave of biotech innovation could determine how the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results